{"news_desk": "SundayBusiness", "print_page": "1", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By GRETCHEN MORGENSON", "person": [{"rank": 1, "role": "reported", "firstname": "Gretchen", "organization": "", "lastname": "MORGENSON"}]}, "abstract": "Gretchen Morgenson Fair Game column observes that investors in drug companies are starting to see the danger in firms like Valeant Pharmaceuticals raising prices indiscriminately to increase stock prices; points out House panel may issue subpoena against Valeant. ", "type_of_material": "News", "word_count": "1070", "lead_paragraph": "Valeant, which has grown by acquiring rivals and slashing their staffs, has drawn the ire of a House panel, which is now considering a subpoena on the company\u2019s price increases.", "pub_date": "2015-10-04T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Valeant\u2019s High-Price Drug Strategy", "content_kicker": "Fair Game", "print_headline": "Side Effects of Hijacking Drug Prices", "kicker": "Fair Game"}, "snippet": "Valeant, which has grown by acquiring rivals and slashing their staffs, has drawn the ire of a House panel, which is now considering a subpoena on the company\u2019s price increases.", "multimedia": [{"height": 126, "url": "images/2015/10/04/business/04gret-web1/04gret-web1-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/10/04/business/04gret-web1/04gret-web1-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 413, "url": "images/2015/10/04/business/04gret-web1/04gret-web1-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "413", "xlarge": "images/2015/10/04/business/04gret-web1/04gret-web1-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/10/04/business/04gret-web1/04gret-web1-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/10/04/business/04gret-web1/04gret-web1-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/10/04/business/valeants-high-price-drug-strategy.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Valeant Pharmaceuticals International Inc", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "3", "is_major": "N", "value": "Stocks and Bonds", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Prices (Fares, Fees and Rates)", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Cummings, Elijah", "name": "persons"}, {"rank": "6", "is_major": "N", "value": "House Committee on Oversight and Government Reform", "name": "organizations"}, {"rank": "7", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}, {"rank": "8", "is_major": "N", "value": "Corporate Taxes", "name": "subject"}, {"rank": "9", "is_major": "N", "value": "Pearson, John Michael (1959- )", "name": "persons"}], "blog": [], "_id": "560ea61638f0d81aa77a547d", "source": "The New York Times"}